For research use only. We do not sell to patients.
Ionizable lipids / Sanofi Lipid 15
Sanofi Lipid 15 chemical structure
Product imageResearch use only
CAT. NO. DC67601Featured

Sanofi Lipid 15

Pack size & price

USD
Total$800
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended
Product overview

Description & Application

Sanofi Lipid 15 is an ionizable lipid investigated in CD8-targeted mRNA-LNPs for transient in vivo CAR-T-cell generation. Published studies report human T-cell transfection, CD22-directed tumor-cell killing, repeat dosing and tumor-burden reduction in humanized mice.

Open full Formulation & Performance →

Literature evidence · DC67601

Formulation & Performance

The reported CAR-T performance belongs to a complete targeted LNP containing Lipid 15, DPG-PEG and a CD8-binding surface conjugate. It is not a property of the isolated lipid or an untargeted four-component LNP.

Lipid 15 is the named ionizable lipid in Lemgart et al. Targeting conjugates and encoded CAR payloads are additional components of the biological platform.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
Sanofi Lipid 15DC67601945.51490.463300
CholesterolDCD-041386.65390.150793
DSPCDC57005790.15100.079015
DPG-PEG2000Not uniquely mappedNot established2Not calculable from disclosed data

Base lipid blend: Lipid 15/cholesterol/DSPC/DPG-PEG2000 = 49:39:10:2 mol%. DPG-PEG is not DMG-PEG2000; 2507 is therefore not assigned to it. The reported N/P design range is 4–6. CD8-targeting VHH conjugate is introduced separately and is not represented as a fifth prefilled bulk-lipid percentage.

Component mass calculator

Not all inputs are assigned to a single verified study formulation; unassigned fields are blank. Enter your own values to calculate a research scenario. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
Sanofi Lipid 15——
Cholesterol——
DSPC——
DPG-PEG2000——

Particle properties and targeting architecture

Study / conditionResultInterpretation
Lipid 15 / DPG-PEG LNP before targeting insertion86 nm; PDI 0.11SI Table S6, initial MBS measurement.
After Nb8 VHH conjugate insertion90 nm; PDI 0.12Targeted particle, not the bare lipid.
After freeze/thaw94 nm; PDI 0.11One tested processing condition; not a shelf-life claim.
Conjugate identityAnti-CD8 Nb8 VHH displayed through a PEG-phospholipid tetherSeparate from the DPG-PEG2000 in the base mixture.

Supplementary Table S6 (printed p. 37) and targeted-LNP methods. Earlier KC2/PEG-content screens are not the final Lipid 15 recipe.

Human T-cell transfection

Study / conditionResultInterpretation
Human PBMCs from four healthy donorsAverage approximately 50% CAR-positive CD8+ T cellsMain Fig. 4; donor variability is retained in the original graph.
CD8-targeted versus CD3-targeted formulationsCD8 targeting supported selective transfection with less nonspecific activation in the tested comparisonsTargeting ligand and LNP architecture contribute to this result.
Transient expressionCAR expression peaked near 24 h and decreased over subsequent daysDetectability and functional tumor killing have different time courses.

Main Figs. 3–4; Supplementary Figs. S16 and S37–S39.

Tumor-cell killing in vitro

Study / conditionResultInterpretation
CD22 CAR delivery to T cellsKilling of CD22-positive tumor targetsAntigen-negative and CD22 knockout controls test specificity.
Repeated target challenge after a single transfectionKilling persisted for up to 8 days in the tested assayTwo tumor-cell additions; not permanent CAR expression.
Repeated transfection settingKilling maintained for up to 10 daysFive tumor-cell additions; distinct from the single-transfection experiment.
Flow cytometry at 120 hSurface CAR became undetectable by the stated method while killing could remain functionalAn assay detection limit is not proof of zero residual receptor.

Main Fig. 5 and Supplementary Fig. S39.

Humanized-mouse delivery, repeat dosing and tumor efficacy

Study / conditionResultInterpretation
Human-PBMC-engrafted NSG mice; 0.3 mg mRNA/kg IV; 24 h>20% CAR-positive human CD8+ T cells in blood, spleen and bone marrowMain Fig. 6; this is a humanized mouse experiment.
Four doses over 2 weeksSimilar blood CD8+ CAR expression after the first and fourth doses; near-complete B-cell depletion in spleen and bone marrowRepeat administration and functional activity in this model.
Nalm6 humanized tumor model; five IV doses of 0.3 mg/kg every 3–4 daysReduced tumor burden over 26 days versus vehicle/control LNPNot a Raji tumor experiment and not a clinical response rate.
Day-26 tissue examinationCD22-positive tumor cells were reported eliminated from examined spleen and liver sectionsA tissue finding does not establish whole-body cure or survival benefit.

Main Figs. 6–8 and Supplementary Tables S10–S11.

Tolerability and immune-response context

Study / conditionResultInterpretation
Four-dose mouse studyNo significant differences in body weight or spleen weight versus controlsLimited endpoints; not a comprehensive long-term toxicology study.
Human MIMIC immune modelSome cytokines increased even with reporter-payload LNPsThe platform was not immunologically inert.
CAR versus reporter payloadAdditional cytokine release accompanied CAR target engagementPayload pharmacology and carrier-mediated effects must be distinguished.
RNA qualityCytokine responses depended on double-stranded-RNA impuritiesReported biological performance assumes the study RNA quality and targeting construct.

Main Fig. 5 and Supplementary Fig. S42; results do not establish human clinical safety.

Original study figures

Original biological figures and supporting information — Original source figures.

References and source locations

  1. Lemgart VT et al. Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies. Molecular Therapy 34 (2026). DOI: 10.1016/j.ymthe.2026.02.020
CAS No.3024023-96-6
Chemical NameSanofi Lipid 15
SynonymsSanofi Lipid-15， Lipid15， Lipid 15
SMILESCCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)N(CCCN(C)C)C(=O)CCC(=O)OC(CCC)CCCCCC
FormulaC58H108O7N2
M.Wt945.51
Purity>95% by ELSD-HPLC
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
Publication
  1. Lemgart VT et al. Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies. Molecular Therapy 34 (2026). DOI: 10.1016/j.ymthe.2026.02.020
Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg10.5763 mL2.1153 mL1.0576 mL
25 mg26.4408 mL5.2882 mL2.6441 mL
50 mg52.8815 mL10.5763 mL5.2882 mL
100 mg105.7630 mL21.1526 mL10.5763 mL
250 mg264.4076 mL52.8815 mL26.4408 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.